146 related articles for article (PubMed ID: 21293287)
1. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
Godoy H; Mhawech-Fauceglia P; Beck A; Miller A; Lele S; Odunsi K
Int J Gynecol Pathol; 2011 Mar; 30(2):139-44. PubMed ID: 21293287
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Hjortkjær M; Waldstrøm M; Jakobsen A; Kanstrup H; Søgaard-Andersen E; Dahl Steffensen K
Int J Gynecol Pathol; 2017 Mar; 36(2):180-189. PubMed ID: 27362900
[TBL] [Abstract][Full Text] [Related]
3. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
4. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
[TBL] [Abstract][Full Text] [Related]
5. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
6. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
Skirnisdottir I; Seidal T
Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
[TBL] [Abstract][Full Text] [Related]
7. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
10. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
Paek J; Lee M; Nam EJ; Kim SW; Kim YT
Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.
Yang S; Li H; Liu Y; Ning X; Meng F; Xiao M; Wang D; Lou G; Zhang Y
Med Oncol; 2013 Mar; 30(1):324. PubMed ID: 23254963
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ASAP1 is associated with poor prognosis in epithelial ovarian cancer.
Hou T; Yang C; Tong C; Zhang H; Xiao J; Li J
Int J Clin Exp Pathol; 2014; 7(1):280-7. PubMed ID: 24427349
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
19. Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
Veskimäe K; Staff S; Grönholm A; Pesu M; Laaksonen M; Nykter M; Isola J; Mäenpää J
Tumour Biol; 2016 Sep; 37(9):11991-11999. PubMed ID: 27155850
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
García-Velasco A; Mendiola C; Sánchez-Muñoz A; Ballestín C; Colomer R; Cortés-Funes H
Clin Transl Oncol; 2008 Jun; 10(6):367-71. PubMed ID: 18558584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
